GlassScriptPhysician profile
Wilfred C Mckenzie
NPI 1245399963
$3,186.53
in general payments reported to CMS, 2019-2025
40 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $546 · 2021: $459 · 2022: $445 · 2023: $579 · 2024: $312 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $469.60 | 2019-2024 | Breztri |
| Novo Nordisk INC | $219.62 | 2019-2025 | Rybelsus, Ozempic |
| Inari Medical, INC. | $193.52 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pfizer INC. | $191.79 | 2019-2025 | |
| Atricure, INC. | $177.77 | 2021 | |
| Abbvie INC. | $177.33 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $152.23 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $151.04 | 2022-2025 | Mounjaro, Zepbound, Lyumjev |
| Astellas Pharma US INC | $145.92 | 2022-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $124.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $119.26 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Angiodynamics, INC. | $107.00 | 2020 | |
| Baxter Healthcare | $83.16 | 2019 | |
| Amgen INC. | $75.96 | 2019-2025 | Evenity |
| Therapeuticsmd, INC. | $74.46 | 2019-2021 |
Show all 38 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilfred Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.